GlassScriptPhysician profile
Jason A Spees
NPI 1033762828
$3,230.24
in general payments reported to CMS, 2019-2025
24 companies · $976 in 2025
The $976 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $436 · 2023: $622 · 2024: $1,070 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Education: $26.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.88 |
| Education | $26.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $486.76 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $471.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $447.63 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $209.39 | 2022-2025 | |
| Viiv Healthcare Company | $202.44 | 2024-2025 | Apretude |
| Shockwave Medical, INC | $168.33 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $157.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $137.95 | 2024-2025 | Auvelity |
| Inspire Medical Systems, INC. | $125.28 | 2021 | |
| Genzyme Corporation | $121.86 | 2025 | |
| Axonics, INC. | $116.50 | 2023 | Axonics |
| Sumitomo Pharma America, INC. | $114.03 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $94.31 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $85.75 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $77.86 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.00 | 2023-2025 | Jardiance |
| Dexcom, INC. | $39.24 | 2024-2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $22.08 | 2024 | Aplenzin |
| Novartis Pharmaceuticals Corporation | $21.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.30 | 2022 | |
| Corcept Therapeutics | $15.88 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $14.61 | 2025 | Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $14.46 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Spees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.